Neuphoria Therapeutics Inc.
NEUP
$4.61
$0.020.44%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 195.92% | -1,130.93% | -230.62% | 505.39% | 57.33% |
| Total Depreciation and Amortization | -0.18% | 0.06% | -0.06% | -0.18% | 0.24% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -297.56% | 275.28% | 226.00% | 57.94% | -290.99% |
| Change in Net Operating Assets | -962.00% | 216.54% | -25.89% | 41.90% | -54.59% |
| Cash from Operations | -91.65% | 14.40% | -19.07% | 447.59% | 14.88% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 813,300.00% | -75.12% | -47.64% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -93.22% | 89.62% | -102.08% |
| Cash from Financing | 13,238.26% | 1,531.41% | -90.10% | -33.51% | -101.98% |
| Foreign Exchange rate Adjustments | 206.76% | -114.09% | -31.49% | 145.72% | -180.62% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 327.48% | 87.61% | -167.67% | 833.05% | -285.06% |